ES2541726T3 - Anticuerpos anti-Notch2 y métodos de uso - Google Patents

Anticuerpos anti-Notch2 y métodos de uso Download PDF

Info

Publication number
ES2541726T3
ES2541726T3 ES09793181.0T ES09793181T ES2541726T3 ES 2541726 T3 ES2541726 T3 ES 2541726T3 ES 09793181 T ES09793181 T ES 09793181T ES 2541726 T3 ES2541726 T3 ES 2541726T3
Authority
ES
Spain
Prior art keywords
antibody
amino acid
region
human
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09793181.0T
Other languages
English (en)
Spanish (es)
Inventor
Christian W. Siebel
Yan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41349057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2541726(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2541726T3 publication Critical patent/ES2541726T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ES09793181.0T 2008-10-01 2009-09-30 Anticuerpos anti-Notch2 y métodos de uso Active ES2541726T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10191708P 2008-10-01 2008-10-01
US101917P 2008-10-01
PCT/US2009/059028 WO2010039832A1 (en) 2008-10-01 2009-09-30 Anti-notch2 antibodies and methods of use

Publications (1)

Publication Number Publication Date
ES2541726T3 true ES2541726T3 (es) 2015-07-23

Family

ID=41349057

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09793181.0T Active ES2541726T3 (es) 2008-10-01 2009-09-30 Anticuerpos anti-Notch2 y métodos de uso

Country Status (18)

Country Link
US (5) US8404239B2 (Direct)
EP (1) EP2334331B1 (Direct)
JP (2) JP5710487B2 (Direct)
KR (1) KR101712214B1 (Direct)
CN (1) CN102170909B (Direct)
AR (1) AR073717A1 (Direct)
AU (1) AU2009298569A1 (Direct)
BR (1) BRPI0913827A2 (Direct)
CA (1) CA2736429A1 (Direct)
CL (1) CL2011000711A1 (Direct)
ES (1) ES2541726T3 (Direct)
IL (1) IL211623A0 (Direct)
MX (1) MX2011002928A (Direct)
PE (1) PE20120080A1 (Direct)
RU (1) RU2580029C2 (Direct)
TW (1) TW201018484A (Direct)
WO (1) WO2010039832A1 (Direct)
ZA (1) ZA201101651B (Direct)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
CN102316897B (zh) 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
BRPI0913827A2 (pt) * 2008-10-01 2020-12-29 Genentech, Inc Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
BR112014008212A2 (pt) * 2011-10-05 2017-06-13 Genentech Inc método para tratar uma condição hepática, método de indução por diferenciação hepática e método de redução de proliferação anormal do ducto biliar
JP2015517529A (ja) * 2012-05-16 2015-06-22 オンコメッド ファーマシューティカルズ インコーポレイテッド Ｎｏｔｃｈ２／３抗体によって癌を治療するための方法
CA2880271C (en) 2012-08-13 2021-10-19 Genentech, Inc. Anti-jagged anitbodies and methods of use
US9944700B2 (en) * 2013-03-13 2018-04-17 Novartis Ag Notch2 binding molecules for treating respiratory diseases
HK1211963A1 (en) 2013-03-15 2016-06-03 豪夫迈．罗氏有限公司 Compositions and methods for diagnosis and treatment of hepatic cancers
TR201810635T4 (tr) 2014-02-12 2018-08-27 Hoffmann La Roche Anti-jagged1 antikorları ve kullanım yöntemleri.
WO2016007775A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2017053939A1 (en) * 2015-09-26 2017-03-30 Kung, Hsing-Jien Method and composition for treatment of hair loss
GB201521447D0 (en) * 2015-12-04 2016-01-20 Ucb Biopharma Sprl De novo antibody design
US10858443B2 (en) 2017-05-31 2020-12-08 Trustees Of Boston University Synthetic notch protein for modulating gene expression
CN116406377A (zh) * 2020-07-17 2023-07-07 基因泰克公司 抗notch2抗体及其使用方法
WO2024216505A1 (zh) * 2023-04-18 2024-10-24 上海洛启生物医药技术有限公司 抗Notch2纳米抗体及其应用
CN120441700B (zh) * 2023-11-21 2026-02-10 兰州大学第二医院 一种抗人notch2单链抗体、编码基因、试剂盒及其用途
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3896111A (en) 1973-02-20 1975-07-22 Research Corp Ansa macrolides
US4151042A (en) 1977-03-31 1979-04-24 Takeda Chemical Industries, Ltd. Method for producing maytansinol and its derivatives
US4137230A (en) 1977-11-14 1979-01-30 Takeda Chemical Industries, Ltd. Method for the production of maytansinoids
US4265814A (en) 1978-03-24 1981-05-05 Takeda Chemical Industries Matansinol 3-n-hexadecanoate
US4307016A (en) 1978-03-24 1981-12-22 Takeda Chemical Industries, Ltd. Demethyl maytansinoids
JPS5562090A (en) 1978-10-27 1980-05-10 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164687A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS5566585A (en) 1978-11-14 1980-05-20 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4256746A (en) 1978-11-14 1981-03-17 Takeda Chemical Industries Dechloromaytansinoids, their pharmaceutical compositions and method of use
JPS55102583A (en) 1979-01-31 1980-08-05 Takeda Chem Ind Ltd 20-acyloxy-20-demethylmaytansinoid compound
JPS55162791A (en) 1979-06-05 1980-12-18 Takeda Chem Ind Ltd Antibiotic c-15003pnd and its preparation
JPS55164685A (en) 1979-06-08 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
JPS55164686A (en) 1979-06-11 1980-12-22 Takeda Chem Ind Ltd Novel maytansinoid compound and its preparation
US4309428A (en) 1979-07-30 1982-01-05 Takeda Chemical Industries, Ltd. Maytansinoids
JPS5645483A (en) 1979-09-19 1981-04-25 Takeda Chem Ind Ltd C-15003phm and its preparation
EP0028683A1 (en) 1979-09-21 1981-05-20 Takeda Chemical Industries, Ltd. Antibiotic C-15003 PHO and production thereof
JPS5645485A (en) 1979-09-21 1981-04-25 Takeda Chem Ind Ltd Production of c-15003pnd
WO1982001188A1 (en) 1980-10-08 1982-04-15 Takeda Chemical Industries Ltd 4,5-deoxymaytansinoide compounds and process for preparing same
US4450254A (en) 1980-11-03 1984-05-22 Standard Oil Company Impact improvement of high nitrile resins
US4315929A (en) 1981-01-27 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Method of controlling the European corn borer with trewiasine
US4313946A (en) 1981-01-27 1982-02-02 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids from Trewia nudiflora
JPS57192389A (en) 1981-05-20 1982-11-26 Takeda Chem Ind Ltd Novel maytansinoid
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
US5053394A (en) 1988-09-21 1991-10-01 American Cyanamid Company Targeted forms of methyltrithio antitumor agents
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
IE20030749A1 (en) * 1991-05-03 2003-11-12 Indiana University Foundation Human notch and delta binding domains in torporythmic proteins, and methods based thereon
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0752248B1 (en) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US20050158859A1 (en) * 1995-09-29 2005-07-21 Yale University Manipulation of non-terminally differentiated cells using the Notch pathway
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US6436650B1 (en) * 1997-07-23 2002-08-20 Yale University Activated forms of notch and methods based thereon
US6692919B1 (en) * 1997-07-23 2004-02-17 Yale University Activated forms of notch and methods based thereon
JP2002526109A (ja) 1998-10-02 2002-08-20 ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ アポトーシス誘導物質と方法
US8084258B2 (en) * 1999-07-12 2011-12-27 University Of Basel Manipulation of tissue of organ type using the notch pathway
DK1318830T3 (da) 2000-09-22 2013-01-28 Genentech Inc Konstitutivt aktiv form af Notch1-receptor eller et anti-Notch1-receptor til behandling af prostatacancer
AU2002226030A1 (en) * 2000-12-04 2002-06-18 Argonex Pharmaceuticals Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7755007B2 (en) 2003-04-17 2010-07-13 K&H Manufacturing, Inc Heated pet mat
AU2005209909B8 (en) * 2004-02-03 2009-01-15 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
WO2006068822A1 (en) 2004-12-20 2006-06-29 Genentech, Inc. Notch receptor agonists and uses
JP5489465B2 (ja) * 2005-12-16 2014-05-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｄｌｌ４アンタゴニストによって腫瘍増殖を阻害する治療方法
WO2008057144A2 (en) * 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
KR101525629B1 (ko) * 2006-10-19 2015-06-26 제넨테크, 인크. 항-Ｎｏｔｃｈ3 작동제 항체 및 Ｎｏｔｃｈ3 관련 질환을 치료하는 데에 있어서의 그의 용도
MX2009006500A (es) * 2006-12-18 2009-06-26 Genentech Inc Anticuerpos antagonistas anti-notch3 y su uso en la prevencion y el tratamiento de enfermedades relacionadas con el receptor notch3.
CA2676008A1 (en) 2007-01-24 2008-07-31 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CN102316897B (zh) * 2008-07-08 2014-11-05 昂考梅德药品有限公司 Notch结合剂和拮抗剂及其应用方法
BRPI0913827A2 (pt) * 2008-10-01 2020-12-29 Genentech, Inc Anticorpo monoclonal, método para inibir a atividade de notch2, método para tratar uma doença, método para tratar uma malignidade, método para tratar um melanoma, usos de um anticorpo e anticorpo nrr anti-notch2
EP3431501A1 (en) * 2009-06-18 2019-01-23 Pfizer Inc Anti notch-1 antibodies

Also Published As

Publication number Publication date
US20140314782A1 (en) 2014-10-23
US20180057589A1 (en) 2018-03-01
JP2012504634A (ja) 2012-02-23
RU2011117237A (ru) 2012-11-10
JP5710487B2 (ja) 2015-04-30
US20170204175A9 (en) 2017-07-20
US8404239B2 (en) 2013-03-26
IL211623A0 (en) 2011-05-31
CN102170909B (zh) 2015-11-25
US20140037643A1 (en) 2014-02-06
AU2009298569A1 (en) 2010-04-08
RU2580029C2 (ru) 2016-04-10
ZA201101651B (en) 2012-06-27
KR20110061600A (ko) 2011-06-09
KR101712214B1 (ko) 2017-03-03
CN102170909A (zh) 2011-08-31
BRPI0913827A2 (pt) 2020-12-29
AR073717A1 (es) 2010-11-24
TW201018484A (en) 2010-05-16
CL2011000711A1 (es) 2012-07-20
MX2011002928A (es) 2011-04-11
US20100080808A1 (en) 2010-04-01
WO2010039832A1 (en) 2010-04-08
CA2736429A1 (en) 2010-04-08
US20150104461A1 (en) 2015-04-16
EP2334331B1 (en) 2015-04-29
EP2334331A1 (en) 2011-06-22
JP2015145379A (ja) 2015-08-13
PE20120080A1 (es) 2012-02-17

Similar Documents

Publication Publication Date Title
ES2541726T3 (es) Anticuerpos anti-Notch2 y métodos de uso
US11390680B2 (en) Anti-Siglec-7 antibodies and methods of use thereof
ES2579323T3 (es) Anticuerpos anti-CD79B e inmunoconjugados y métodos de uso
US10676525B2 (en) Anti-TREM2 antibodies and methods of use thereof
US20250026827A1 (en) Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof
KR101299073B1 (ko) 사람 인터루킨-13에 대한 항체 및 이의 용도
EP2446904B1 (en) Anti-CD22 antibodies, their immunoconjugates and uses thereof
US7812133B2 (en) Anti-OX40L antibodies and methods using same
EP2483311B1 (en) Anti-Notch3 antagonistic antibodies for treating of a gamma-secretase inhibitor positive T-cell leukemia that does not respond to an anti-Notch1 antagonistic antibody.
KR20070107687A (ko) Ｂｒ３과 결합하는 폴리펩티드, 및 그의 용도
BRPI1014016B1 (pt) anticorpos humanizados para receptor tipo toll 2 e usos dos mesmos.
RS66604B1 (sr) Humanizovana antitela na faktor komplementa c1q i njihova upotreba
KR20160078499A (ko) 종양 괴사 인자-유사 리간드 1a 특이적 항체 및 그의 조성물 및 용도
US20190085094A1 (en) Immunoglobulin variants with altered binding to protein a
US20230024528A1 (en) Methods of use of anti-trem2 antibodies
US20230183341A1 (en) Methods of use of anti-trem2 antibodies
US12065475B2 (en) T cell receptors and fusion proteins thereof
US20250084165A1 (en) Methods of use of anti-trem2 antibodies
US20220403022A1 (en) Anti-TIGIT Antibodies and Uses Thereof
US20110171231A1 (en) ANTI-PlGF ANTIBODIES AND METHODS USING SAME
HK40101643A (en) Anti-trem2 antibodies and methods of use thereof
HK1169805B (en) Anti-cd22 antibodies, their immunoconjugates and uses thereof